600645 Vcanbio Cell & Gene Engineering Corp.,Ltd.
- 22.07
- +0.22+1.01%
Vcanbio Cell & Gene Engineering Corp.,Ltd. News
Zhongyuan Kyowa: Announcement of Zhongyuan Kyowa Cytogenetic Engineering Co., Ltd. on obtaining a notice of acceptance of the wholly-owned subsidiary drug clinical trial application
Announcement of Resolutions of the 13th Interim Board Meeting of the 11th Zhongyuan Union Cytogenetic Engineering Co., Ltd.
Special report on the storage and actual use of funds raised by Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. for the 2024 semi-annual period
Announcement of Resolutions of the 12th Board Meeting of the 11th Zhongyuan Union Cytogenetic Engineering Co., Ltd.
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on participating in the 2024 semi-annual report performance briefing for listed companies in Tianjin and an online investor reception day
Announcement of Resolutions of the 5th Meeting of the 11th Supervisory Committee of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Announcement of the resolution of the 11th extraordinary meeting of the 11th board of directors of Vcanbio Cell & Gene Engineering Corp., Ltd.
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on holding the 2023 Annual Results Briefing
Announcement on abnormal stock trading fluctuations of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Reply to the inquiry letter on abnormal stock trading fluctuations of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Special report on the storage and actual use of funds raised by Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. in 2023
Dongxing Securities Co., Ltd.'s special inspection opinion on the storage and use of funds raised by Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. in 2023
Dongxing Securities Co., Ltd.'s verification opinion on the extension of the fund-raising investment project of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the use of idle funds raised to temporarily supplement working capital
Dongxing Securities Co., Ltd.'s verification opinion on the use of idle funds raised by Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. to temporarily supplement working capital
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. Audit Report
Special explanation on the capital occupation of the controlling shareholders and other related parties of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Verification report on the storage and use of funds raised by Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. Internal Control Audit Report
2023 Independent Director Debriefing Report of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. (Hou Xinyi)
Analysis
Price Target
No Data
No Data